Brainstorm Cell Therapeutics (BCLI) Tops Q4 EPS by 1c

Note: EPS may not be comparable

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• Spotify (SPOT) jumps 10% as Q1 revenue, gross margins beat Street's estimates
• Philip Morris (PM) beats Q1 earnings, revenue estimates; issues upbeat guidance